Abstract
Introduccion: Acinetobacter baumannii es un bacilo Gram negativo oportunista, clasiicado por la Sociedad Americana de Enfermedades Infecciosas como uno de los seis más importantes microorganismos multirresistentes alrededor del mundo. En Colombia, según informes del Ministerio de Salud y Protección Social, dentro de los microorganismos multirresistente aislados en unidades de cuidados intensivos del país en el año 2014, A. baumannii representó el 3,1%. Objetivo: revisar los aspectos relevantes en la epidemiología, hábitat natural, factores de riesgo y virulencia para la infección por A. baumannii, sus manifestaciones clínicas y diferentes mecanismos de resistencia frente a múltiples fármacos, las estrategias de manejo actual y en desarrollo para enfrentar este microorganismo y mecanismos encaminados a prevenir y controlar la aparicion del mismo. Metodologia de búsqueda: se realizó una búsqueda en las bases de datos LILACS, PubMed, SciELO, Imbiomed, Cochrane, Clinicalkey, Biblioteca Virtual en Salud, de 890 articulos se seleccionaron 254. Resultados: las especies de Acinetobacter pueden ser aisladas de objetos animados e inanimados. Crecen en casi todas las muestras de suelos y agua fresca. En el medio hospitalario, estos microorganismos han sido aislados de humidiicadores, equipos de ventilación, hojas de laringoscopio, cortinas, piel del personal de salud, colchones, cojines y otros equipos. Sus factores de virulencia no han sido dilucidados en totalidad, entre ellos se encuentran proteína de membrana externa OmpaA, lipopolisacáridos y polisacáridos capsulares, vesículas de membrana externa, fosfolipasa C y D y alteración de las proteínas de unión de penicilina. Las manifestaciones clínicas son variadas, principalmente en entorno asociado a cuidado de la salud. Sus mecanismo de resistencia son múltiples, los cuales se agrupan en tres categorías: enzimas inactivadoras de antimicrobianos, limitación del acceso a las dianas bacterianas y mutaciones que alteran las dianas o funciones celulares. Los carbapenémicos aún son considerados como agentes de elección para las infecciones graves por A. Baumannii, con opciones terapeuticas adicionales como sulbactam, tobramicina, amikacina, tigeciclina, minociclina, doxiciclina y colistina. Investigadores han reportado interrupción de la transmisión de A. baumannii posterior al reforzamiento de medidas para prevención y control de infecciones, tales como higiene de manos, uso de métodos de barrera (tapabocas, guantes, entre otros) y exhaustiva limpieza y desinfección del ambiente hospitalario. En otros casos la transmisión es más difícil de interrumpir, requiriendo aislamiento de pacientes, asignación de personal asistencial para vigilancia, cultivos de vigilancia activa y cierre de las unidades. Conclusiones: consideramos primordial el manejo de los pacientes de acuerdo a la localización de la infección y el patrón de resistencia presente en las cepas de la unidad en particular. Es importante la creación de protocolos institucionales con escalones terapéuticos, considerando el sitio de la infección, gravedad del paciente, sensibilidad de la cepa propia de cada institución y el uso previo de antibióticos. MÉD.UIS. 2016;29(2):113-35.
Palabras clave: Acinetobacter Baumannii. Bacterias Gramnegativas. Epidemiologia. Factores de riesgo. Farmacorresistencia bacteriana.
Virulencia.
References
Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired
pneumonia and ventilator-associated pneumonia: recent
advances in epidemiology and managment. Curr Opin Pulm Med
;19(3):216–228.
Rosenthal VD, Bijie H, Maki DG, Mehta Y, Apisarnthanarak A,
Medeiros EA et al. International Nosocomial Infection Control
Consortium (INICC) report, data summary of 36 countries, for
–2009. Am J Infect Control 2012;40(5):396–407.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal
SM et al. Surviving Sepsis Campaign: international guidelines for
management of severe sepsis and septic shock, 2012. Crit Care
Med 2013;41(2):580-637.
Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A
et al. Risk factors for drug-resistant pathogens in communityacquired
and healthcare-associated pneumonia. Am J Respir Crit
Care Med 2013;188(8):985–995.
Aliberti S, Cilloniz C, Chalmers JD, Zanaboni AM, Cosentini
R, Tarsia P et al. Multidrug-resistant pathogens in hospitalised
patients coming from the community with pneumonia: an
European perspective. Thorax 2013;68:997–9.
Torres A, Cilloniz C, Ferrer M, Gabarrus A, Polverino E, Villegas
S et al. Bacteraemia and antibiotic-resistant pathogens in
community acquired pneumonia: risk and prognosis. Eur Respir
J 2015;45(5):1353–63.
Center for Diseases Control and Prevention. Antibiotic
Resistance Threat report 2013. [Internet]. 2013 [Citado 30 Nov
. Disponible en: http://www.cdc.gov/drugresistance/threatreport-2013/pdf/ar-threats-2013-508.pdf.
Alekshun MN, Levy S. Molecular mechanisms of antibacterial
multidrug resistance. Cell 2007;128(6):1037–50.
Joly-Guillou M. Clinical impact and pathogenicity of
Acinetobacter. Clin Microbiol Infect 2005;11(11):868–73.
Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG
et al. Bad bugs need drugs: an update on the development pipeline
from the Antimicrobial Availability Task Force of the Infectious
Diseases Society of America. Clin Infect Dis 2006;42(5):657–68.
Bouvet P, Grimont P. Taxonomy of the genus Acinetobacter
with the recognition of Acinetobacter baumannii sp. nov.,
Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp.
nov., and Acinetobacter junii sp. nov. and emended descriptions
of Acinetobacter calcoaceticus and Acinetobacter lwoffii. Int J
Syst Bacteriol 1986;36: 228–40.
Montefour K, Frieden J, Hurst S, Helmich C, Headley D, Martin M
et al. Acinetobacter baumannii: an emerging multidrug-resistant
pathogen in critical care. Crit Care Nurse 2008;28(1):15-25.
Turton J, Kaufmann M, Gill M, Pike R, Scott P, Fishbain J, et
al. Comparison of Acinetobacter baumannii isolates from the
United Kingdom and the United States that were associated
with repatriated casualties of the Iraq conflict. J Clin Microbiol.
;44:2630-4.
Sebeny PJ, Riddle MS, Petersen K. Acinetobacter baumannii skin
and soft-tissue infection associated with war trauma. Clin Infect
Dis. 2008;47(4):444-9.
Bassetti M, Ginocchio F, Mikulska M. New treatment options
against gram-negative organisms. Crit Care 2011;15(2):215.
Rice LB. Federal funding for the study of antimicrobial
resistance in nosocomial pathogens: no ESKAPE. J Infect Dis
;197(8):1079-81.
Beijerinck M. Pigmenten als oxydatieproducten gevormd door
bacterien. Vers Konin Akad Wet Ams 1911;19:1092–103. [Artículo
de revista]
Brisou J, Prevot AR. Studies on bacterial taxonomy. The revision
of species under Achromobacter group. Ann Inst Pasteur
;86(6):722–8.
Lessel EF. International Committee on Nomenclature of Bacteria
Subcommittee on nomenclature of Moraxella and allied bacteria.
Int J Syst Bacteriol 1971;21(2):213–4.
Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii:
emergence of a successful pathogen. Clin Microbiol Rev
;21(3):538-82.
Di Nocera PP, Rocco F, Giannouli M, Triassi M, Zarrilli R. Genome
organization of epidemic Acinetobacter baumannii strains. BMC
Microbiol 2011;11:224.
Gerner-Smidt P, Tjernberg I, Ursing J. Reliability of phenotypic
tests for identification of Acinetobacter species. J Clin Microbiol
;29(2):277-82.
Seifert H, Dijkshoorn L, Gerner-Smidt P, Pelzer N, Tjernberg I,
Vaneechoutte M. Distribution of Acinetobacter species on human
skin: comparison of phenotypic and genotypic identification
methods. J Clin Microbiol. 1997;35(11):2819-25.
Vaneechoutte M, Dijkshoorn L, Tjernberg I, Elaichouni A, De
Voz P, Claeys G, et al. Identification of Acinetobacter genomic
species by amplified ribosomal DNA restriction analysis. J Clin
Microbiol. 1995;33(1):11-5.
Janssen P, Maquelin K, Coopman R, Tjernberg I, Bouvet P, Kersters
K, et al. Discrimination of Acinetobacter genomic species by
AFLP fingerprinting. Int J Syst Bacteriol. 1997;47(4):1179-87.
Gerner-Smidt P. Ribotyping of the Acinetobacter calcoaceticusAcinetobacter
baumannii complex. J Clin Microbiol. 1992;30
(10):2680-5.
Ehrenstein B, Bernards A, Dijkshoorn L, Smidt P, Towner K,
Bouvet P, et al. Acinetobacter species identification by using
tRNA spacer fingerprinting. J Clin Microbiol. 1996;34 (10): 2414-
Dolzani L, Tonin E, Lagatolla C, Prandin L, Bragadin C.
Identification of Acinetobacter isolates in the A. calcoaceticus-A.
baumannii complex by restriction analysis of the 16S-23S rRNA
intergenic-spacer sequences. J Clin Microbiol. 1995;33(5):1108-
Chang H, Wei Y, Dijkshoorn L, Vaneechoutte M, Tang C, Chang
T. Species-level identification of isolates of the Acinetobacter
calcoaceticus-Acinetobacter baumannii complex by sequence
analysis of the 16S-23S rRNA gene spacer region. J Clin Microbiol.
;43(4):1632-9.
La Scola B, Raoult D. Acinetobacter baumannii in human body
louse. Emerg Infect Dis. 2004;10(9):1671-3.
Richards M, Edwards J, Culver D, Gaynes R. Nosocomial
infections in medical intensive care units in the United States.
National Nosocomial Infections Surveillance System. Crit Care
Med. 1999;27(5):887-92.
Fluit A, Jones M, Schmitz F, Acar J, Gupta R, Verhoef J.
Antimicrobial susceptibility and frequency of occurrence of
clinical blood isolates in Europe from the SENTRY antimicrobialsurveillance program, 1997 and 1998. Clin Infect Dis.
;30(3):454-60.
Gales A, Jones R, Forward K, Linares J, Sader H, Verhoef J.
Emerging importance of multidrugresistant Acinetobacter species
and Stenotrophomonas maltophilia as pathogens in seriously
ill patients: geographic patterns, epidemiological features, and
trends in the SENTRY. Antimicrobial Surveillance Program
(1997-1999). Clin Infect Dis. 2001;32(Suppl 2):104-13.
Jones R. Global aspects of antimicrobial resistance among
key bacterial pathogens. Results from the 1997-1999 SENTRY
Antimicrobial Program. Clin Infect Dis. 2001;32(Suppl 2):81-156.
Sader H, Jones R, Gales A, Silva J, Pignatari A, The SENTRY
participants group (latin america). SENTRY Antimicrobial
Surveillance Program Report: Latin American and Brazilian
results for 1997 through 2001. Braz J Infect Dis. 2004;8(1):25-79.
Unal S, Garcia J. Activity of meropenem and comparators against
Pseudomonas aeruginosa and Acinetobacter sp. isolated in
the MYSTIC Program, 2002–2004. Diagn Microbiol Infect Dis.
;53(4):265–271.
Bronharo M, Sgambatti S, Silbert S, Gales A, Jones R, Sader H.
Resistance trends of Acinetobacter sp. in Latin America and
characterization of international dissemination of multi-drug
resistant strains: five-year report of the SENTRY Antimicrobial
Surveillance Program. Int J Infect Dis. 2004;8:284–291.
Gales A, Tognim M, Reis A, Jones R, Sader H. Emergence of an
IMP-like metallo-enzyme in an Acinetobacter baumannii clinical
strain from a Brazilian teaching hospital. Diagn Microbiol Infect
Dis. 2003;45(1):77–9.
Sader H, Castanheira M, Mendes R, Toleman M, Walsh T, Jones R.
Dissemination and diversity of metallo-beta-lactamases in Latin
America: report from the SENTRY Antimicrobial Surveillance
Program. Int J Antimicrob Agents. 2005;25(1):57–61.
Dalla-Costa L, Coelho J, Souza H, Castro M, Stier C, Bragagnolo
K, et al. Outbreak of carbapenem-resistant Acinetobacter
baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J
Clin Microbiol. 2003;41(7):3403–3406.
Villegas M, Kattan J, Correa A, Lolans K, Guzman A, Woodford
N, et al. Dissemination of Acinetobacter baumannii clones with
OXA-23 carbapenemase in Colombian hospitals. Antimicrob
Agents Chemother. 2007;51(6):2001–4.
Coelho J, Woodford N, Afzal-Shah M, Livermore D. Occurrence
of OXA-58-like carbapenemases in Acinetobacter sp. collected
over 10 years in three continents. Antimicrob Agents Chemother.
;50(2):756–8.
Ovalle M. Vigilancia de Resistencia antimicrobiana a través del
software Whonet Informe año 2014. 2015. Minsalud Colombia
[internet] Disponible en: https://www.minsalud.gov.co/sites/rid/
Lists/BibliotecaDigital/RIDE/IA/INS/informe%20-resistenciawhonet%20-2014.pdf#search=acinetobacter%2520baumannii.
Hernandez C, Blanco V, Motoa G, Correa A, Maya J, Cadena et
al. Evolución de la resistencia antimicrobiana de bacilos Gram
negativos en unidades de cuidados intensivos en Colombia.
Biomédica. 2014;34(Supl. 1):91-100.
Falagas M, Bliziotis I, Siempos I. Attributable mortality of
Acinetobacter baumannii infections in critically ill patients: a
systematic review of matched cohort and case-control studies.
Crit Care. 2006;10(2):48.
Sunenshine R, Wright M, Maragakis L, Harris A, Song X, Hebden
J, et al. Multidrug-resistant Acinetobacter infection mortality rate
and length of hospitalization. Emerg Infect Dis. 2007;13(1):97–
Maragakis L, Perl T. Acinetobacter baumanii: Epidemiology,
Antimicrobial Resistance and Treatment Options. Clin Infec Dis.
;46(8):1254-63.
Falagas M, Kopterides P, Siempos L. Attributable mortality of
Acinetobacter baumanii infection among critically ill patients.
Clin Infect Dis. 2006;43:389-90.
Owens R, Rice L. Hospital based strategies for combating
resistance. Clin Inf Dis. 2006;42(Suppl.4):173-181.
Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia
involving Acinetobacter baumanii in critically ill patients: a
matched cohort study. Intensive Care Med. 2003;29(3):471-5.
Bergogne-Berezin E, Towner K. Acinetobacter sp. as nosocomial
pathogens: microbiological, clinical, and epidemiological
features. Clin Microbiol Rev. 1996;9(2):148-65.
Allen D, Hartman B. Acinetobacter Species. In: Mandell GL,
Bennett JE, Dolin R. Douglas and Bennett editors. Principles
and Practice of Infectious Diseases. 6th ed. Elsevier Churchill
Livingstone, Philadelphia. 2005:2632-5.
Chen M, Hsueh P, Lee L, Yu C, Yang P, Luh K. Severe community
acquired pneumonia due to Acinetobacter baumannii. Chest.
;120(4):1072-7.
Mahgoub S, Ahmed J, Glatt A. Underlying characteristics of
patients harboring highly resistant Acinetobacter baumannii. Am
J Infect Control. 2002;30:386-90.
Playford E, Craig J, Iredell J. Carbapenem-resistant Acinetobacter
baumanii in intensive care unit patients: risk factors for
acquisition, infection and their consequences. J Hosp Infect.
;65(3):204-211.
Lee S, Kim N, Choi S, Hyong T, Chung J, Woo J, et al. Risk
factors for adquisition of Imipenem resistant Acinetobacter
baumanii: a case-control study. Antimicrob Agents Chemother.
;48(1):224-8.
Husni R, Goldstein L, Arroliga A, Hall G, Fatica C, Stoller J, et al.
Risk factors for an outbreak of multidrug resistant Acinetobacter
nosocomial pneumonia among intubated patients. Chest.
;115(5):1378-82.
García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J,
Jiménez-Jiménez F, Pérez-Paredes C, Barrero-Almodóvar A,
et al. Risk factors for Acinetobacter baumannii nosocomial
bacteremia in critically ill patients: a cohort study. Clin Infect
Dis. 2001;33(7):939-46.
Gerner-Smidt P. Acinetobacter: epidemiological and taxonomic
aspects. APMIS Suppl. 1994;47:1-41.
Cefai C, Richards J, Gould FK, McPeake P. An outbreak of
Acinetobacter respiratory tract infection resulting from
incomplete disinfection of ventilatory equipment. J Hosp Infect.
;15(2):177-82.
Hirai Y. Survival of bacteria under dry conditions; from a
viewpoint of nosocomial infection. J Hosp Infect. 1991;19(3):191-
Seifert H, Baginski R, Schulze A, Pulverer G. The distribution
of Acinetobacter species in clinical culture materials. Zentralbl
Bakteriol. 1993;279(4):544–552. AR
Berlau J, Aucken H, Malnick H, Pitt T. Distribution of
Acinetobacter species on skin of healthy humans. Eur J Clin
Microbiol Infect Dis. 1999;18(3):179–83.
Buxton AE, Anderson RL, Werdegar D, Atlas E. Nosocomial
respiratory tract infection and colonization with Acinetobacter
calcoaceticus. Epidemiologic characteristics. Am J Med.
;65(3):507-13.
Eveillard M, Kempf M, Belmonte O, Pailhori H, Joly-Guillou M.
Reservoirs of Acinetobacter baumannii outside the hospital and
potential involvement in emerging human community-acquired
infections. Int J Infect Dis. 2013;17(10):802–05.
Choi CH, Lee EY, Lee YC, Park TI, Kim HJ, Hyun SH, et al. Outer
membrane protein 38 of Acinetobacter baumannii localizes to
the mitochondria and induces apoptosis of epithelial cells. Cell
Microbiol. 2005;7(8):1127-38.
Gaddy JA, Actis LA. Regulation of Acinetobacter baumannii
biofilm formation. Future Microbiol. 2009;4(3):273-8.
Kim SW, Choi CH, Moon DC, Jin JS, Lee JH, Shin JH, et al. Serum
resistance of Acinetobacter baumannii through the binding
of factor H to outer membrane proteins. FEMS Microbiol Lett.
;301:224-31.
Luke N, Sauberan S, Russo T, et al. Identification and
characterization of a glycosyltransferase involved in
Acinetobacter baumannii lipopolysaccharide core biosynthesis.
Infect Immun. 2010;78(5):2017–23.
Knapp S, Wieland CW, Florquin S, Pantophlet R, Dijkshoorn L,
Tshimbalanga N, et al. Differential roles of CD14 and toll-like
receptors 4 and 2 in murine Acinetobacter pneumonia. Am J
Respir Crit Care Med. 2006;173(1):122–29.
Fregolino E, Gargiulo V, Lanzetta R, Parrilli M, Holst O, Castro
C. Identification and structural determination of the capsular
polysaccharides from two Acinetobacter baumannii clinical
isolates, MG1 and SMAL. Carbohydr Res. 2011;346(7):973–77.
Russo TA, Luke NR, Beanan JM, Olson R, Sauberan SL,
MacDonald U, et al. The K1 capsular polysaccharide of
Acinetobacter baumannii strain 307-0294 is a major virulence
factor. Infect Immun. 2011;78(9):3993–4000.
Ellis TN, Kuehn MJ. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol Rev.
;74(1):81–94.
Kwon SO, Gho YS, Lee JC, Kim SI. Proteome analysis of outer
membrane vesicles from a clinical Acinetobacter baumannii
isolate. FEMS Microbiol Lett. 2009;297(2):150–6.
Jin JS, Kwon SO, Moon DC, Gurung M, Lee JH, Kim SI,
Lee JC. Acinetobacter baumannii secretes cytotoxic outer
membrane protein A via outer membrane vesicles. PLoS ONE.
;6(2):e17027.
Jacobs AC, Hood I, Boyd KL, Olson PD, Morrison JM, Carson S,
et al. Inactivation of phospholipase D diminishes Acinetobacter
baumannii pathogenesis. Infect Immun. 2010;78(5):1952–62.
Camarena L, Bruno V, Euskirchen G, Poggio S, Snyder M.
Molecular mechanisms of ethanol-induced pathogenesis revealed
by RNA-sequencing. PLoS Pathog. 2010;6(4):e1000834.
Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P. The
penicillin-binding proteins: structure and role in peptidoglycan
biosynthesis. FEMS Microbiol Rev. 2008;32(2):234–58.
Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa
E, Aldabó-Pallás T, Cayuela A, Marquez-Vácaro JA, et al.
Acinetobacter baumannii ventilator-associated pneumonia:
epidemiological and clinical findings. Intensive Care Med.
;31(5):649-55.
Luna CM, Aruj PK. Nosocomial Acinetobacter pneumonia.
Respirology. 2007;12(6):787-91.
Gaynes R., Edwards JR, National Nosocomial Infections
Surveillance System. Overview of nosocomial infections caused
by gram-negative bacilli. Clin Infect Dis. 2005;41(6):848–54.
Anstey NM, Currie BJ, Hassell M, Palmer D, Dwyer B, Seifert H.
Community-acquired bacteremic Acinetobacter pneumonia in
tropical Australia is caused by diverse strains of Acinetobacter
baumannii, with carriage in the throat in at-risk groups. J Clin
Microbiol. 2002;40(2):685–6.
Leung WS, Chu CM, Tsang KY, Lo FH, Lo KF, Ho PL. Fulminant
community-acquired Acinetobacter baumannii pneumonia as a
distinct clinical syndrome. Chest. 2006;129(1):102–9.
Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel
RP, Edmond MB. Nosocomial bloodstream infections in US
hospitals: analysis of 24,179 cases from a prospective nationwide
surveillance study. Clin Infect Dis. 2004;39:309-17.
Trottier V, Segura PG, Namias N, King D, Pizano LR, Schulman
CI. Outcomes of Acinetobacter baumannii infection in critically
ill burned patients. J Burn Care Res. 2007;28(2):248–54.
Metan G, Alp E, Aygen B, Sumerkan B. Carbapenem-resistant
Acinetobacter baumannii: an emerging threat for patients
with post-neurosurgical meningitis. Int J Antimicrob Agents.
;29(1):112–3.
Nunez ML, Martinez-Toldos MC, Bru M, Simarro E, Segovia
M, Ruiz J. Appearance of resistance to meropenem during the
treatment of a patient with meningitis by Acinetobacter. Scand J
Infect Dis. 1998;30(40):421–3.
O’Neill E, Humphreys H, Phillips J, Smyth EG. Third-generation
cephalosporin resistance among Gram-negative bacilli causing
meningitis in neurosurgical patients: significant challenges in
ensuring effective antibiotic therapy. J Antimicrob Chemother.
;57(2):356–9.
Menon T, Shanmugasundaram S, Nandhakumar B, Nalina K,
Balasubramaniam. Infective endocarditis due to Acinetobacte
baumannii complex a case report. Indian J Pathol Microbiol.
;49(4):576–8.
Olut A, Erkek E. Early prosthetic valve endocarditis due to
Acinetobacter baumannii: a case report and brief review of the
literature. Scand J Infect Dis. 2005;37(11-12):919–21.
Rizos I, Papathanasiou S, Rigopoulos A, Barbetseas J,
Stefanadis C, Tsiodras S. Prosthetic valve endocarditis due to
Acinetobacter spp: a rare case and literature review. Am J Med
Sci. 2007;333(3):197–9.
Starakis I, Blikas A, Siagris D, Marangos M, Karatza C, Bassaris
H. Prosthetic valve endocarditis caused by Acinetobacter lwoffi:
a case report and review. Cardiol Rev. 2006;14:45–9.
Corrigan KM, Harmis NY, Willcox MD. Association of
Acinetobacter species with contact lens-induced adverse
responses. Cornea. 2001;20(5):463–6.
Kau HC, Tsai CC, Kao SC, Hsu WM, Liu JH. Corneal ulcer of the
side port after phacoemulsification induced by Acinetobacter
baumannii. J Cataract Refract Surg. 2002;28(5):895–7.
Levy J, Oshry T, Rabinowitz R, Lifshitz T. Acinetobacter corneal
graft ulcer and endophthalmitis: report of two cases. Can J
Ophthalmol. 2005;40(1):79–82.
Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel
S, Diekema DJ, et al. Antimicrobial resistance among gramnegative
bacilli causing infections in intensive care unit patients
in the United States between 1993 and 2004. J Clin Microbiol.
;45(10):3352-9.
Seifert H, Baginski R, Schulze A, Pulverer G. Antimicrobial
susceptibility of Acinetobacter species. Antimicrob Agents
Chemother. 1993;37(4):750-3.
Afzal-Shah M, Woodford N, Livermore DM. Characterization of
OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases
associated with carbapenem resistance in clinical isolates of
Acinetobacter baumannii. Antimicrob Agents Chemother.
;45(2):583–8.
Rice L. Challenges in indentifying new antimicrobial agents
effective for treating infections with Acinetobacter baumanii and
Pseudomonas aeruginosa. Clin Infect Dis. 2006;43(2):S100-5.
Bou G, Cerveró G, Domínguez MA, Quereda C, MartínezBeltrán
J. Characterization of a nosocomial outbreak caused
by a multiresistant Acinetobacter baumannii strain with a
carbapenem-hydrolyzing enzyme: high-level carbapenem
resistance in A. baumannii is not due solely to the presence of
beta-lactamases. J Clin Microbiol. 2000;38(9):3299–305.
Fernandez-Cuenca F, Martínez-Martínez L, Conejo MC, Ayala
JA, Perea EJ, Pascual A. Relationship between beta-lactamase
production, outer membrane protein and penicillin-binding
protein profiles on the activity of carbapenems against clinical
isolates of Acinetobacter baumannii. J Antimicrob Chemother.
;51(3):565–74.
Nordmann P, Poirel L. Emerging carbapenemases in gramnegative
aerobes. Clin Microbiol Infect. 2002;8:321-31.
Weldhagen G, Poirel L, Nordmann P. Ambler class A extendedspectrum
beta-lactamases in Pseudomonas aeruginosa:
novel developments and clinical impact. Antimicrob Agents
Chemother. 2003;47(8):2385-92.
Poirel L, Menuteau O, Agoli N, Catton C, Nordmann P. Outbreak
of extended-spectrum β -lactamase VEB-1-producing isolates of
Acinetobacter baumannii in a French hospital. J Clin Microbiol.
;41:3542-7.
Danes C, Navia M, Ruiz J, Marco F, Jurado A, Jimenez de Anta
M, Vila J. Distribution of beta-lactamases in Acinetobacter
baumannii clinical isolates and the effect of Syn 2190 (AmpC
inhibitor) on the MICs of different beta-lactam antibiotics. J
Antimicrob Chemother. 2002;50(2):261–4.
Vila J, Marcos A, Marco F, Abdalla S, Vergara Y, Reig R, Gomez
R, Jimenez de Anta T. In vitro antimicrobial production of
beta-lactamases, aminoglycoside-modifying enzymes, and
chloramphenicol acetyltransferase by and susceptibility of
clinical isolates of Acinetobacter baumannii. Antimicrob. Agents
Chemother. 1993;37(1):138–41.
Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter
baumannii: mechanisms and epidemiology. Clin Microbiol
Infect. 2006;12(9):826–36.
Cornaglia G, Riccio M, Mazzariol A, Lauretti L, Fontana R,
Rossolini G. Appearance of IMP-1 metallo-beta-lactamase in
Europe. Lancet. 1999;353(9156):899–900.
Da Silva G, Correia M, Vital C, Ribeiro G, Sousa J, Leitao R,
Peixe L, Duarte A. Molecular characterization of bla(IMP-5),
a new integron-borne metallo-beta-lactamase gene from an
Acinetobacterbaumannii nosocomial isolate in Portugal. FEMS
Microbiol Lett. 2002;215(1):33-9.
Lee K, Lee W, Uh Y, Ha G, Cho J, Chong Y. VIM- and IMPtype
metallo-beta-lactamase-producing Pseudomonas sp.
and Acinetobacter sp. in Korean hospitals. Emerg Infect Dis.
;9(7):868–71.
Lim Y, Shin K, Kim J. Distinct antimicrobial resistance patterns
and antimicrobial resistance-harboring genes according to
genomic species of Acinetobacter isolates. J Clin Microbiol.
;45(3):902–5.
Tsakris A, Ikonomidis A, Pournaras S, Tzouvelekis L, Sofianou
D, Legakis N, Maniatis A. VIM-1 metallo-beta-lactamase in
Acinetobacter baumannii. Emerg Infect Dis. 2006;12(6):981–3.
Yum J, Yi K, Lee H, Yong D, Lee K, Kim J, Rossolini G, Chong
Y. Molecular characterization of metallo-beta-lactamase-producing Acinetobacter baumannii and Acinetobacter
genomospecies 3 from Korea: identification of two new integrons
carrying the blaVIM-2 gene cassettes. J Antimicrob Chemother.
;49(5):837–40.
Lee K, Yum J, Yong D, Lee H, Kim H, Docquier J, Rossolini G, Chong
Y. Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a
class 1 integron from Acinetobacter baumannii clinical isolates
from Korea. Antimicrob Agents Chemother. 2005;49(11):4485–
Hujer K, Hamza N, Hujer A, Perez F, Helfand M, Bethel C,
Thomson J, Anderson V, Barlow M, Rice L, Tenover F, Bonomo
R. Identification of a new allelic variant of the Acinetobacter
baumannii cephalosporinase, ADC-7 beta-lactamase: defining a
unique family of class C enzymes. Antimicrob Agents Chemother.
;49(7):2941–8.
Bou G, Martinez J. Cloning, nucleotide sequencing, and analysis
of the gene encoding an AmpC beta-lactamase in Acinetobacter
baumannii. Antimicrob Agents Chemother. 2000;44:428–32.
Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H, Reynaud
A. AmpC cephalosporinase hyperproduction in Acinetobacter
baumannii clinical strains. J Antimicrob Chemother.
;52(4):629–35.
Paton R, Miles R, Hood J, Amyes S. ARI-1: β-lactamasemediated
imipenem resistance in Acinetobacter baumannii. Int
J Antimicrob Agents. 1993;2(2):81–8.
Donald H, Scaife W, Amyes S, Young H. Sequence analysis of
ARI-1, a novel OXA beta-lactamase, responsible for imipenem
resistance in Acinetobacter baumannii 6B92. Antimicrob Agents
Chemother. 2000;44(1):196–9.
Scaife W, Young H, Paton R, Amyes S. Transferable imipenemresistance
in Acinetobacter species from a clinical source. J
Antimicrob Chemother. 1995;36(3):585–6.
Afzal-Shah M, Woodford N, Livermore D. Characterization of
OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases
associated with carbapenem resistance in clinical isolates of
Acinetobacter baumannii. Antimicrob Agents Chemother.
;45(2):583–8.
Brown S, Amyes S. OXA (beta)-lactamases in Acinetobacter:the
story so far. J Antimicrob Chemother. 2006;57(1):1–3.
Bou G, Oliver A, Martinez J. OXA-24, a novel class D betalactamase
with carbapenemase activity in an Acinetobacter
baumannii clinical strain. Antimicrob. Agents Chemother.
;44(6):1556–61.
Da Silva G, Quinteira S, Bertolo E, Sousa J, Gallego L, Duarte A,
Peixe L. Long-term dissemination of an OXA-40 carbapenemase
producing Acinetobacter baumannii clone in the Iberian
Peninsula. J Antimicrob Chemother. 2004;54:255–8.
Bertini A, Giordano A, Varesi P, Villa L, Mancini C, Carattoli A.
First report of the carbapenem-hydrolyzing oxacillinase OXA-58
in Acinetobacter baumannii isolates in Italy. Antimicrob Agents
Chemother. 2006;50:2268–9.
Bogaerts P, Naas T, Wybo I, Bauraing C, Soetens O, Pierard D,
Nordmann P, Glupczynski Y. Outbreak of infection by carbapenemresistant
Acinetobacter baumannii producing the carbapenemase
OXA-58 in Belgium. J Clin Microbiol. 2006;44(11):4189–92.
Poirel L, Marque S, Heritier C, Segonds C, Chabanon G, Nordmann
P. OXA-58, a novel class D β-lactamase involved in resistance to
carbapenems in Acinetobacter baumannii. Antimicrob Agents
Chemother. 2005;49(1):202–8.
Marque S, Poirel L, Heritier C, Brisse S, Blasco M, Filip R, Coman
G, Naas T, Nordmann P. Regional occurrence of plasmidmediated
carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter
spp. in Europe. J Clin Microbiol. 2005;43:4885–8.
Brown S, Young H, Amyes S. Characterisation of OXA-51, a
novel class D carbapenemase found in genetically unrelated
clinical strains of Acinetobacter baumannii from Argentina. Clin
Microbiol Infect. 2005;11(1):15–23.
Heritier C, Poirel L, Fournier P, Claverie J, Raoult D, Nordmann
P. Characterization of the naturally occurring oxacillinase of
Acinetobacter baumannii. Antimicrob Agents Chemother.
;49(10):4174–9.
Turton J, Woodford N, Glover J, Yarde S, Kaufmann M, Pitt T.
Identification of Acinetobacter baumannii by detection of the bla-
xa-51-like carbapenemase gene intrinsic to this species. J Clin
Microbiol. 2006;44(8):2974–6.
Costa S, Woodcock J, Gill M, Wise R, Barone A, Caiaffa H,
Levin A. Outer-membrane proteins pattern and detection
of betalactamases in clinical isolates of imipenem-resistant
Acinetobacter baumannii from Brazil. Int J Antimicrob Agents.
;13(3):175–82.
Mussi M, Limansky A, Viale A. Acquisition of resistance
to carbapenems in multidrug-resistant clinical strains of
Acinetobacter baumannii: natural insertional inactivation of
a gene encoding a member of a novel family of beta-barrel
outer membrane proteins. Antimicrob Agents Chemother.
;49(4):1432–40.
Heritier C, Poirel L, Lambert T, Nordmann P. Contribution of
acquired carbapenem-hydrolyzing oxacillinases to carbapenem
resistance in Acinetobacter baumannii. Antimicrob Agents
Chemother. 2005;49(12):3198–202.
Gehrlein M, Leying H, Cullmann W, Wendt S, Opferkuch W.
Imipenem resistance in Acinetobacter baumanii is due to altered
penicillinbinding proteins. Chemotherapy. 1991;37(6):405–12.
Limansky A, Mussi M, Viale A. Loss of a 29-kilodalton outer
membrane protein in Acinetobacter baumannii is associated with
imipenem resistance. J Clin Microbiol. 2002;40(12):4776–8.
Siroy A, Molle V, Lemaitre C, Vallenet D, Pestel M, Cozzone
A, Jouenne T. Channel formation by CarO, the carbapenem
resistance-associated outer membrane protein of Acinetobacter
baumannii. Antimicrob Agents Chemother. 2005;49(12):4876–
Quale J, Bratu S, Landman D, Heddurshetti R. Molecular
epidemiology and mechanisms of carbapenem resistance in
Acinetobacter baumannii endemic in New York City. Clin Infect
Dis. 2003;37(2):214–20.
Bou G, Cervero G, Dominguez M, Quereda C, Martinez
J. Characterization of a nosocomial outbreak caused by
a multiresistant Acinetobacter baumannii strain with a
carbapenem-hydrolyzing enzyme: high-level carbapenem
resistance in A. baumannii is not due solely to the presence of
beta-lactamases. J Clin Microbiol. 2000;38(8):3299–305.
Gribun A, Nitzan Y, Pechatnikov I, Hershkovits G, Katcoff
D. Molecular and structural characterization of the HMP-AB
gene encoding a pore-forming protein from a clinical isolate of
Acinetobacter baumannii. Curr Microbiol. 2003;47(5):434–43.
Clark R. Imipenem resistance among Acinetobacter baumannii:
association with reduced expression of a 33–36 kDa outer
membrane protein. J Antimicrob Chemother. 1996;38(2):245–51.
Vila J, Marti S, Sanchez J. Porins, efflux pumps and multidrug
resistance in Acinetobacter baumannii. J Antimicrob Chemother.
;59(6):1210–5.
Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, et al.
Comparative genomics of multidrug resistance in Acinetobacter
baumannii. PLoS Genet. 2006;2(1):7.
Higgins P, Wisplinghoff H, Stefanik D, Seifert H. Selection of
topoisomerase mutations and overexpression of adeB mRNA
transcripts during an outbreak of Acinetobacter baumannii. J
Antimicrob Chemother. 2004;54(4):821–23.
Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell
division-type efflux pump involved in aminoglycoside resistance
in Acinetobacter baumannii strain BM4454. Antimicrob Agents
Chemother. 2001;45(12):3375–380.
Marchand I, Damier L, Courvalin P, Lambert T. Expression of
the RND-type efflux pump AdeABC in Acinetobacter baumannii
is regulated by the AdeRS two-component system. Antimicrob
Agents Chemother. 2004;48(9):3298–304.
Nemec A, Maixnerova M, Van der Reijden TJ, Van den Broek PJ,
Dijkshoorn L. Relationship between the AdeABC efflux system
gene content, netilmicin susceptibility and multidrug resistance
in a genotypically diverse collection of Acinetobacter baumannii
strains. J Antimicrob Chemother. 2007;60(3):483–9.
Towner K. Clinical importance and antibiotic resistance of
Acinetobacter spp. Proceedings of a symposium held on 4 - 5
November 1996 at Eilat, Israel. J Med Microbiol. 1997;46(9):721-
Doi Y, Adams J, Yamane K, Paterson D. Identification of 16S
rRNA methylase-producing Acinetobacter baumannii clinical
strains in North America. Antimicrob Agents Chemother.
;51(11):4209–10.
Lee H, Yong D, Yum JH, Roh KH, Lee K, Yamane K, et al.
Dissemination of 16S rRNA methylase-mediated highly amikacinresistant
isolates of Klebsiella pneumoniae and Acinetobacter baumannii in Korea. Diagn. Microbiol Infect Dis. 2006;56(3):305–
Yamane K, Wachino J, Doi Y, Kurokawa H, Arakawa Y. Global
spread of multiple aminoglycoside resistance genes. Emerg Infect
Dis. 2005;11(6):951–3.
Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging
resistance mechanism against aminoglycosides. Clin Infect Dis.
;45:88–94.
Su X, Chen J, Mizushima T, Kuroda T, Tsuchiya T. AbeM, an
H+-coupled Acinetobacter baumannii multidrug efflux pump
belonging to the MATE family of transporters. Antimicrob Agents
Chemother. 2005;49(10):4362–64.
Seward R, Owner T. Molecular epidemiology of quinolone
resistance in Acinetobacter spp. Clin Microbiol Infect.
;4:248-54.
Ribera A, Ruiz J, Jiminez de Anta MT, Vila J. Effect of an efflux
pump inhibitor on the MIC of nalidixic acid for Acinetobacter
baumannii and Stenotrophomonas maltophilia clinical isolates. J
Antimicrob Chemother. 2002;49(4):697–8.
Fluit AC, Florijn A, Verhoef J, Milatovic D. Presence of tetracycline
resistance determinants and susceptibility to tigecycline and
minocycline. Antimicrob Agents Chemother. 2005;49(4):1636–
Guardabassi L, Dijkshoorn L, Collard JM, Olsen JE, Dalsgaard
A. Distribution and in-vitro transfer of tetracycline resistance
determinants in clinical and aquatic Acinetobacter strains. J Med
Microbiol. 2000;49(10):929–36.
Ribera A, Roca I, Ruiz J, Gibert I, Vila J. Partial characterization
of a transposon containing the tet(A) determinant in a clinical
isolate of Acinetobacter baumannii. J Antimicrob Chemother.
;52(3):477–80.
Ribera A, Ruiz J, Vila J. Presence of the Tet M determinant in a
clinical isolate of Acinetobacter baumannii. Antimicrob Agents
Chemother. 2003;47(7):2310–12.
Peleg A, Adams J, Paterson D. Tigecycline efflux as a mechanism
for nonsusceptibility in Acinetobacter baumannii. Antimicrob
Agents Chemother. 2007;51(6):2065–69.
Ruzin A, Keeney D, Bradford PA. AdeABC multidrug efflux
pump is associated with decreased susceptibility to tigecycline in
Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J
Antimicrob Chemother. 2007;59(5):1001–4.
Reis A, Luz D, Tognim M, Sader H, Gales A. Polymyxin-Resistant
Acinetobacter spp. isolates: What is Next? Emerg Infect Dis.
;9(8):1025-7.
Gales AC, Jones RN, Sader HS. Global assessment of the
antimicrobial activity of polymyxin B against 54,731 clinical
isolates of gram-negative bacilli: report from the SENTRY
antimicrobial surveillance programme (2001–2004). Clin
Microbiol Infect. 2006;12(4):315–321.
Conrad RS, Galanos C. Fatty acid alterations and polymyxin B
binding by lipopolysaccharides from Pseudomonas aeruginosa
adapted to polymyxin B resistance. Antimicrob Agents
Chemother. 1989;33(10):1724-8.
Peterson AA, Fesik SW, McGroarty EJ. Decreased binding of
antibiotics to lipopolysaccharides from polymyxin-resistant
strains of Escherichia coli and Salmonella typhimurium.
Antimicrob Agents Chemother. 1987;31:230–7.
Nicas TI, Hancock RE. Outer membrane protein H1 of
Pseudomonas aeruginosa: involvement in adaptive and
mutational resistance to ethylenediaminetetraacetate, polymyxin
B, and gentamicin. J Bacteriol. 1980;143(2):872–8.
Young ML, Bains M, Bell A, Hancock RE. Role of Pseudomonas
aeruginosa outer membrane protein OprH in polymyxin and
gentamicin resistance: isolation of an OprH-deficient mutant by
gene replacement techniques. Antimicrob Agents Chemother.
;36(11):2566–2568.
Young LS, Sabel AL, Price CS. Epidemiologic, clinical, and
economic evaluation of an outbreak of clonal multidrug-resistant
Acinetobacter baumanii infection in a surgical intensive care
unit. Infect Control Hosp Epidemiol. 2007;28(11):1247-54.
Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, Ho SW, et al.
Pandrug-resistant Acinetobacter baumannii causing nosocomial
infections in a university hospital, Taiwan. Emerg Infect Dis.
;8(8):827-32.
Lee CM, Lim HK, Liu CP, Tseng HK. Treatment of pandrug
resistant Acinetobacter baumannii. Scand J Infect Dis.
;37(3):195-9.
Urban C, Go E, Mariano N, Rahal J. Interaction of sulbactam,
clavulanic acid and tazobactam with penicillin-binding
proteins of imipenem-resistant and –susceptible Acinetobacter
baumannii. FEMS Microb Lett. 1995;125:193-7.
Brauers J, Frank U, Kresken M, Rodloff AC, Seifert H. Activities
of various beta-lactams and beta-lactam/beta-lactamase inhibitor
combinations against Acinetobacter baumannii and Acinetobacter
DNA group 3 strains. Clin Microbiol Infect. 2005;11(1):24–30.
Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. In vitro
activities of the beta-lactamase inhibitors clavulanic acid,
sulbactam, and tazobactam alone or in combination with betalactams
against epide miologically characterized multidrugresistant
Acinetobacter baumannii strains. Antimicrob Agents
Chemother. 2004;48(5):1586–92.
Urban C, Go E, Mariano N, Berger BJ, Avraham I, Rubin D, et al.
Effect of sulbactam on infections caused by imipenem-resistant
Acinetobacter calcoaceticus biotype anitratus. J Infect Dis.
;167(2):448–51.
Smolyakov R, Borer A, Riesenberg K, Schlaeffer F , Alkan M,
Porath A, et al. Nosocomial multi-drug resistant Acinetobacter
baumannii bloodstream infection: risk factors and outcome with
ampicillin-sulbactam treatment. J Hosp Infect. 2003;54(1):2-8.
Jiménez-Mejías ME, Pachón J, Becerril B, Palomino-Nicás J,
Rodríguez-Cobacho A, Revuelta M. Treatment of multidrugresistant
Acinetobacter baumannii meningitis with ampicillin/
sulbactam. Clin Infect Dis. 1997;24(5):932–35.
Levin AS, Levy CE, Manrique AE, Medeiros EA, Costa SF. Severe
nosocomial infections with imipenem-resistant Acinetobacter
baumannii treated with ampicillin/sulbactam. Int J Antimicrob
Agents. 2003;21(1):58–62.
Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G. High-dose
ampicillin-sulbactam as an alternative treatment of late-onset
VAP from multidrug-resistant Acinetobacter baumannii. Scand J
Infect Dis. 2007;39(1):38–43.
Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA.
Comparison of ampicillin-sulbactam and imipenem-cilastatin for
the treatment of acinetobacter ventilator-associated pneumonia.
Clin Infect Dis. 2002;34(11):1425–30.
Fraenkel CJ, Ullberg M, Bernander S, Ericson E, Larsson P,
Rydberg J, et al. In vitro activities of three carbapenems against
recent bacterial isolates from severely ill patients at Swedish
hospitals. Scand J Infect Dis. 2006;38(10):853–9.
Ikonomidis A, Pournaras S, Maniatis A, Legakis N, Tsakris
A. Discordance of meropenem versus imipenem activity
against Acinetobacter baumannii. Int J Antimicrob Agents.
;28(4):376–7.
Jones RN, Deshpande L, Fritsche TR, Sader HS. Determination
of epidemic clonality among multidrug-resistant strains of
Acinetobacter sp. and Pseudomonas aeruginosa in the MYSTIC
Programme (USA, 1999–2003). Diagn Microbiol Infect Dis.
;49(3):211–6.
Lesho E, Wortmann G, Moran K, Craft D. Fatal Acinetobacter
baumanniiinfection with discordant carbapenem susceptibility.
Clin Infect Dis. 2005;41:758–9.
Paterson D, Depestel D. Doripenem. Clin Infect Dis. 2009;49:291–
Murray CK, Hospenthal DR. Treatment of multidrug resistant
Acinetobacter. Curr Opin Infect Dis. 2005;18(6):502-6.
Gounden R, Bamford C, van Zyl-Smit R, Cohen K, Maartens G.
Safety and effectiveness of colistin compared with tobramycin
for multidrug resistant Acinetobacter baumannii infections. BMC
Infect Dis. 2009;9:26.
Bishburg E, Bishburg K. Minocycline an old drug for a new
century: emphasis on methicillin-resistant Staphylococcus
aureus (MRSA) and Acinetobacter baumannii. Int J Antimicrob
Agents. 2009;34(5):395–401.
Wood G, Hanes S, Boucher B, Croce M, Fabian T. Tetracyclines
for treating multidrugresistant Acinetobacter baumannii
ventilatorassociated pneumonia. Intensive Care Med.
;29:2072-6.
Fluit A, Florijn A, Verhoef J, Milatovic D. Presence of tetracycline
resistance determinants and susceptibility to tigecycline and
minocycline. Antimicrob Agents Chemother. 2005;49:1636–8.
Fritsche T, Strabala P, Sader H, Jones R. Activity of tigecycline
tested against non-fermentative gram-negative bacilli other than P. aeruginosa. 42nd Annual Meeting of IDSA; 2004; Boston, USA.
Abstract 323.
Poulakou G, Kontopidou F, Paramythiotou E, Kompoti M, Katsiari
M, Manias E, et al. Tigecycline in the treatment of infections
from multi-drug resistant gram-negative pathogens. J Infect.
;58(4):273–84.
Peleg A, Potoski B, Rea R, Adams J, Sethi J, Capitano B, et al.
Acinetobacter baumannii bloodstream infection while receiving
tigecycline: a cautionary report. J Antimicrob Chemother.
;59(1):128–31.
Livermore D. Tigecycline: what is it, and where should it be
used?. J Antimicrob Chemother. 2005;56:611-4.
Anthony K, Fishman N, Linkin D, Gasink L, Edelstein P,
Lautenbach E. Clinical and microbiological outcomes of serious
infections with multidrug-resistant gram-negative organisms
treated with tigecicline. Clin Infect Dis. 2008;46:567-70.
Li J, Nation R, Milne R, Turnidge J, Coulthard K. Evaluation
of colistin as an agent against multi-resistant Gram-negative
bacteria. Int J Antimicrob Agents. 2005;25:11-25.
Falagas M, Kasiakou S. Colistin: The revival of polymyxins for
the management of multidrugresistant gram-negative bacterial
infections. Clin Infect Dis. 2005;40:1333-41.
Evans M, Feola D, Rapp R. Polymyxin B sulfate and colistin: old
antibiotics for emerging multiresistant gram-negative bacteria.
Ann Pharmacother. 1999;33:960-7.
Levin A, Barone A, Penco J, Santos M, Marinho I, Arruda E, et
al. Intravenous colistin as therapy for nosocomial infections
caused by multidrug-resistant Pseudomonas aeruginosa and
Acinetobacter baumannii. Clin Infect Dis. 1999;28:1008–11.
Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W, Chelly H, et
al. Colistin as a salvage therapy for nosocomial infections caused
by multidrug-resistant bacteria in the ICU. Int J Antimicrob
Agents. 2006;28:366–9.
Shirawi N, Memish Z, Cherfan A, Shimemeri A. Post-neurosurgical
meningitis due to multidrug resistant Acinetobacter treated with
intratecal colistina: case report and review of the literature. J
Chemother. 2006;18:554-558.
Garnacho J, Ortiz C, Jimenez F, Barrero A, García J, Bernabeu M,
et al. Treatment of multidrug-resistant Acinetobacter baumannii
ventilator-associated pneumonia (VAP) with intravenous colistin:
a comparison with imipenem-susceptible VAP. Clin Infect Dis.
;36:1111–8.
Linden P, Paterson D. Parenteral and inhaled colistin for
treatment of ventilator-associated pneumonia. Clin Infect Dis.
;43(Suppl 2):89-94.
Kasiakou S, Michalopoulos A, Soteriades E, Samonis G,
Sermaides G, Falagas M. Combination therapy with intravenous
colistin for management of infections due to multidrug-resistant
gram-negative bacteria in patients without cystic fibrosis.
Antimicrob Agents Chemother. 2005;49:3136–46.
Katragkou A, Roilides E. Successful treatment of multidrugresistant
Acinetobacter baumannii central nervous system
infections with colistin. J Clin Microbiol. 2005;43:4916–7.
Fulnecky E, Wright D, Scheld W, Kanawati L, Shoham S.
Amikacin and colistin for treatment of Acinetobacter baumannii
meningitis. J Infect. 2005;51:249-51.
Benifla M, Zucker G, Cohen A, Alkan M. Successful treatment
of Acinetobacter meningitis with intrathecal polymyxin E. J
Antimicrob Chemother. 2004;54:290–2.
Al S, Memish Z, Cherfan A, Al S. Post-neurosurgical meningitis
due to multidrug-resistant Acinetobacter baumanii treated with
intrathecal colistin: case report and review of the literature. J
Chemother. 2006;18:554–8.
Ng J, Gosbell I, Kelly J, Boyle M, Ferguson J. Cure of multiresistant
Acinetobacter baumannii central nervous system infections with
intraventricular or intrathecal colistin: case series and literature
review. J Antimicrob Chemother. 2006;58:1078–81.
Falagas M, Bliziotis I, Tam V. Intraventricular or intrathecal
use of polymyxins in patients with gram-negative meningitis:
a systematic review of the available evidence. Int J Antimicrob
Agents. 2007;29:9–25.
Alvarez C, Cortes J, Ovalle M. Boletin GREBO 2015. GREBO
[Internet]. 2015. Disponible en: http://www.grebo.org/grebo_site/
jgrebo/documentos/Boletin_Grebo_2015.pdf
Rahal J. Novel antibiotic combinations against infections with
almost completely resistant Pseudomonas aeruginosa and
Acinetobacter species. Clin Infect Dis. 2006;43(Suppl 2):S95–9.
Chait R, Craney A, Kishony R. Antibiotic interactions that select
against resistance. Nature. 2007;446:668–71.
Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats
J, et al. Antibiotic combinations for serious infections caused
by carbapenem- resistant Acinetobacter baumanii in a mouse
pneumonia model. J Antimicrob Chemother. 2004;54:1085-91.
Saballs M, Pujol M, Tubau F, Peña C, Montero A, Domínguez
M, et al. Rifampicin/imipenem combination in the treatment
of carbapenem-resistant Acinetobacter baumanii infections. J
Antimicrob Chemother. 2006;58:697-700.
Bernabeu M, Pichardo C, García A, Pachón M, Ibáñez J, Jiménez
M, et al. Pharmacokinetic/ pharmacodynamic assessment of
the in-vivo efficacy of Imipenem alone or in combination with
amikacina for the treatment of experimental multiresistant
Acinetobacter baumanii pneumonia. Clin Microbiol Infect.
;11:319–25.
Ermertcan S, Hosgor M, Tunger O, Cosar G. Investigation of
synergism of meropenem and ciprofloxacin against Pseudomonas
aeruginosa and Acinetobacter strains isolated from intensive care
unit infections. Scand J Infect Dis. 2001;33:818–21.
Joly-Guillou M, Wolff M, Farinotti R, Bryskier A, Carbon C. In vivo
activity of levofloxacin alone or in combination with imipenem
or amikacin in a mouse model of Acinetobacter baumannii
pneumonia. J Antimicrob Chemother. 2000;46:827–30.
Sader H, Rhomberg P, Jones R. In vitro activity of beta-lactam
antimicrobial agents in combination with aztreonam tested against
metallo-beta-lactamase-producing Pseudomonas aeruginosa and
Acinetobacter baumannii. J Chemother. 2005;17:622–7.
Howard A, O´Donoghue M, Feeney A. Acinetobacter baumannii:
an emerging opportunistic pathogen. Virulence. 2012;3:243-50.
Mihu M, Martinez L. Novel therapies for treatment of multi-drug
resistant Acinetobacter baumannii skin infections. Virulence.
;2:97-102.
Coates A, Hu Y. Novel approaches to developing new antibiotics
for bacterial infections. Br J Pharmacol. 2007;152:1147-54.
Poole K. Overcoming multidrug resistance in gramnegative
bacteria. Curr Opin Investig Drugs. 2003;4:128-39.
Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, et al. Use of
bacteriophage in the treatment of experimental animal bacteremia
from imipenem-resistant Pseudomonasaeruginosa. Int J Mol Med.
;17:309–17.
Yang H, Liang L, Lin S, Jia S. Isolation and characterization of
a virulent bacteriophage AB1 of Acinetobacter baumannii. BMC
Microbiol. 2010;10:131.
Shankar R, He L, Szilagyi A, Muthu K, Gamelli R, Filutowicz M,
et al. A novel antibacterial gene transfer treatment for multidrugresistant
Acinetobacter baumannii-induced burn sepsis. J Burn
Care Res. 2007;28:6-12.
Dadachova E, Burns T, Bryan R, Apostolidis C, Brechbiel
M, Nosanchuk J, et al. Feasibility of radioimmunotherapy of
experimental pneumococcal infection. Antimicrob Agents
Chemother. 2004;48:1624-9.
Dadachova E, Nakouzi A, Bryan R, Casadevall A. Ionizing
radiation delivered by specific antibody is therapeutic against a
fungal infection. Proc Natl Acad Sci U S A. 2003;100:10942-7.
Dadachova E, Patel M, Toussi S, Apostolidis C, Morgenstern A,
Brechbiel M, et al. Targeted killing of virally infected cells by
radiolabeled antibodies to viral proteins. PLoS Med. 2006;3:427.
McConnell M, Domínguez J, Smani Y, López R, Docobo F,
Pachón J. Vaccination with outer membrane complexes elicits
rapid protective immunity to multidrug-resistant Acinetobacter
baumannii. Infect Immun. 2011;79:518-26.
Islam A, Singh K, Ismail A. Demonstration of an outer membrane
protein that is antigenically specific for Acinetobacter baumannii.
Diagn Microbiol Infect Dis. 2011;69:38-44.
Castano A, Mroz P, Wu M, Hamblin M. Photodynamic therapy
plus low-dose cyclophosphamide generates antitumor immunity
in a mouse model. Proc Natl Acad Sci U S A. 2008;105:5495-500.
Demidova T, Hamblin M. Photodynamic therapy targeted to
pathogens. Int J Immunopathol Pharmacol. 2004;17:245-54.
Dai T, Tegos G, Lu Z, Huang L, Zhiyentayev T, Franklin M, et
al. Photodynamic therapy for Acinetobacter baumannii burn
infections in mice. Antimicrob Agents Chemother. 2009;53:3929-
Friedman A, Han G, Navati M, Chacko M, Gunther L, Alfieri A, et al. Sustained release nitric oxide releasing nanoparticles:
characterization of a novel delivery platform based on nitrite
containing hydrogel/glass composites. Nitric Oxide. 2008;19:12-20.
Mihu M, Sandkovsky U, Han G, Friedman J, Nosanchuk J,
Martinez L. The use of nitric oxide releasing nanoparticles as a
treatment against Acinetobacter baumannii in wound infections.
Virulence. 2010;1(2):62-7.
Siegel J, Rhinehart E, Jackson M, Chiarello L, Healthcare
Infection Control Practices Advisory Committee. Management of
multidrug-resistant organisms in health care settings, 2006. Am J
Infect Control. 2007;35(10 Suppl 2):S165-93.
Dijkshoorn L, Nemec A, Seifert H. An increasing threat in
hospitals: multidrug-resistant Acinetobacter baumanii. Nat Rev
Microbiol. 2007;5(12):939-51.
Wilks M, Wilson A, Warwick S, Price E, Kennedy D, Ely A, et
al. Control of an outbreak of multidrug-resistant Acinetobacter
baumannii—calcoaceticus colonization and infection in
an intensive care unit (ICU) without closing the ICU or
placing patients in isolation. Infect Control Hosp Epidemiol.
;27(7):654-8.
Zarrilli R, Casillo R, Di Popolo A, Tripodi MF, Bagattini M,
Cuccurullo S, et al. Molecular epidemiology of a clonal outbreak
of multidrug-resistant Acinetobacter baumannii in a university
hospital in Italy. Clin Microbiol Infect. 2007;13(5):481-9.
Kraniotaki E, Manganelli R, Platsouka E, Grossato A, Paniara
O, Palú G. Molecular investigation of an outbreak of multidrugresistant
Acinetobacter baumannii, with characterisation of class
integrons. Int J Antimicrob Agents. 2006;28(3):193-9.
Podnos Y, Cinat M, Wilson S, Cooke J, Gornick W, Thrupp
L. Eradication of multi-drug resistant Acinetobacter from an
intensive care unit. Surg Infect (Larchmt). 2001;2(4):297-301.
Aygün G, Demirkiran O, Utku T, Mete B, Urkmez S, Yilmaz M, et
al. Environmental contamination during a carbapenem-resistant
Acinetobacter baumannii outbreak in an intensive care unit. J
Hosp Infect. 2002;52(4):259-62.
Lee S, Kim N, Choi S, Hyong Kim T, Chung J, Woo J, et al. Risk
factors for acquisition of imipenem-resistant Acinetobacter
baumannii: a case-control study. Antimicrob Agents Chemother.
;48(1):224-8.
Kim YA, Choi JY, Kim CK, Kim CO, Kim MS, Choi SH, et al. Risk
factors and outcomes of bloodstream infections with metallo–
beta–lactamase-producing Acinetobacter. Scand J Infect Dis.
;40(3):234-40.
Villers D, Espaze E, Coste M, Giauffret F, Ninin E, Nicolas F, et al.
Nosocomial Acinetobacter baumannii infections: microbiological
and clinical epidemiology. Ann Intern Med. 1998;129(3):182-9.
Abbo A, Navon S, Hammer O, Krichali T, Siegman Y, Carmeli Y.
Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis.
;11(1):22-9.
Cornaglia G, Akova M, Amicosante G, Cantón R, Cauda R,
Docquier J, et al. Metallo-beta-lactamases as emerging resistance
determinants in Gram-negative pathogens: open issues. Int J
Antimicrob Agents. 2007;29(4):380-8.
Nemec A, Dijkshoorn L, van der Reijden T. Long-term
predominance of two pan-European clones among multi-resistant
Acinetobacter baumannii strains in the Czech Republic. J Med
Microbiol. 2004;53(2):147-53.
Van den Broek P, Arends J, Bernards A, De Brauwer E, Mascini E,
van der Reijden T, et al. Epidemiology of multiple Acinetobacter
outbreaks in the Netherlands during the period 1999-2001. Clin
Microbiol Infect. 2006;12(9):837-43.
Suller M, Russell A. Antibiotic and biocide resistance in
methicillin-resistant Staphylococcus aureus and vancomycinresistant
enterococcus. J Hosp Infect. 1999;43(4):281-91.
Thomas L, Maillard J, Lambert R, Russell A. Development of
resistance to chlorhexidine diacetate in Pseudomonas aeruginosa
and the effect of a “residual” concentration. J Hosp Infect.
;46(4):297–303.
Wisplinghoff H, Schmitt R, Wöhrmann A, Stefanik D, Seifert
H. Resistance to disinfectants in epidemiologically defined
clinical isolates of Acinetobacter baumannii. J Hosp Infect.
;66(2):174-81.
Kaye K, Harris A, Samore M, Carmeli Y. The case-case-control
study design: addressing the limitations of risk factor studies
for antimicrobial resistance. Infect Control Hosp Epidemiol.
;26(4):346-51.